$475 Million is the total value of Kynam Capital Management, LP's 37 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 38.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTRA | Buy | NATERA INC | $88,445,000 | +101.4% | 2,018,360 | +62.9% | 18.64% | +66.2% |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $54,618,000 | +13.0% | 2,272,915 | -9.5% | 11.51% | -6.8% |
| CLDX | Buy | CELLDEX THERAPEUTICS INC NEW | $44,980,000 | +47.3% | 1,600,127 | +41.3% | 9.48% | +21.6% |
| VERA | Buy | VERA THERAPEUTICS INCcl a | $32,736,000 | +58.0% | 1,536,181 | +0.9% | 6.90% | +30.3% |
| UTHR | New | UNITED THERAPEUTICS CORP DEL | $31,618,000 | – | 151,009 | +100.0% | 6.66% | – |
| SNY | New | SANOFIsponsored adr | $22,812,000 | – | 600,000 | +100.0% | 4.81% | – |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $20,510,000 | +200.4% | 1,000,000 | +69.5% | 4.32% | +147.8% |
| BIIB | Sell | BIOGEN INC | $20,025,000 | +24.4% | 75,000 | -5.0% | 4.22% | +2.6% |
| PCVX | Sell | VAXCYTE INC | $16,767,000 | +6.5% | 698,638 | -3.5% | 3.53% | -12.2% |
| BNR | Buy | BURNING ROCK BIOTECH LTDsponsored ads | $16,022,000 | +28.0% | 6,703,863 | +55.9% | 3.38% | +5.6% |
| New | GSK PLCsponsored adr | $14,715,000 | – | 500,000 | +100.0% | 3.10% | – | |
| COGT | Sell | COGENT BIOSCIENCES INC | $14,699,000 | +63.0% | 985,155 | -1.5% | 3.10% | +34.4% |
| CNCE | Buy | CONCERT PHARMACEUTICALS INC | $11,209,000 | +166.2% | 1,673,041 | +67.3% | 2.36% | +119.7% |
| TVTX | Sell | TRAVERE THERAPEUTICS INC | $10,268,000 | -65.7% | 416,729 | -66.3% | 2.16% | -71.7% |
| LQDA | Buy | LIQUIDIA CORPORATION | $9,207,000 | +40.7% | 1,692,402 | +12.8% | 1.94% | +16.1% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS IN | $8,936,000 | -87.3% | 131,220 | -94.0% | 1.88% | -89.5% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $7,325,000 | +22.6% | 6,720,148 | +67.6% | 1.54% | +1.2% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $7,066,000 | -26.9% | 676,849 | -24.8% | 1.49% | -39.7% |
| BCRX | Sell | BIOCRYST PHARMACEUTICALS INC | $5,482,000 | -44.7% | 435,117 | -53.5% | 1.16% | -54.4% |
| WVE | Sell | WAVE LIFE SCIENCES LTD | $5,045,000 | -8.5% | 1,397,479 | -17.6% | 1.06% | -24.5% |
| MCRB | Buy | SERES THERAPEUTICS INC | $4,962,000 | +459.4% | 772,820 | +198.8% | 1.05% | +360.8% |
| AKUS | Buy | AKOUOS INC | $4,856,000 | +169.8% | 718,394 | +87.2% | 1.02% | +122.4% |
| GOSS | Sell | GOSSAMER BIO INC | $4,628,000 | -76.5% | 386,349 | -83.6% | 0.98% | -80.6% |
| PTGX | New | PROTAGONIST THERAPEUTICS INC | $4,377,000 | – | 519,212 | +100.0% | 0.92% | – |
| OLMA | Buy | OLEMA PHARMACEUTICALS INC | $3,863,000 | +281.0% | 1,399,633 | +461.6% | 0.81% | +214.3% |
| CNTA | Sell | CENTESSA PHARMACEUTICALS PLCsponsored ads | $2,941,000 | -20.3% | 731,521 | -3.5% | 0.62% | -34.3% |
| AFMD | Sell | AFFIMED N V | $1,394,000 | -28.2% | 676,675 | -3.5% | 0.29% | -40.7% |
| PBYI | Sell | PUMA BIOTECHNOLOGY INC | $1,327,000 | -19.7% | 559,769 | -3.5% | 0.28% | -33.6% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $1,039,000 | -80.5% | 28,792 | -83.5% | 0.22% | -83.9% |
| CNTB | CONNECT BIOPHARMA HLDGS LTDads | $954,000 | +48.4% | 739,649 | 0.0% | 0.20% | +22.6% | |
| RLMD | New | RELMADA THERAPEUTICS INCput | $803,000 | – | 300,000 | +100.0% | 0.17% | – |
| CABA | Sell | CABALETTA BIO INC | $343,000 | -40.9% | 527,805 | -3.5% | 0.07% | -51.4% |
| TCDA | New | TRICIDA INCcall | $338,000 | – | 260,000 | +100.0% | 0.07% | – |
| TCDA | New | TRICIDA INCput | $122,000 | – | 97,600 | +100.0% | 0.03% | – |
| NLTX | Sell | NEOLEUKIN THERAPEUTICS INC | $77,000 | -39.8% | 120,368 | -3.5% | 0.02% | -51.5% |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $45,000 | -72.9% | 90,188 | -3.5% | 0.01% | -78.6% |
| LQDA | New | LIQUIDIA CORPORATIONcall | $13,000 | – | 507,700 | +100.0% | 0.00% | – |
| KRTX | Exit | KARUNA THERAPEUTICS INCput | $0 | – | -38,900 | -100.0% | -0.15% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INCput | $0 | – | -50,000 | -100.0% | -0.24% | – |
| FATE | Exit | FATE THERAPEUTICS INC | $0 | – | -81,064 | -100.0% | -0.51% | – |
| MRUS | Exit | MERUS N V | $0 | – | -103,627 | -100.0% | -0.60% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEWcall | $0 | – | -246,400 | -100.0% | -0.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SYNDAX PHARMACEUTICALS INC | 8 | Q3 2023 | 12.3% |
| CELLDEX THERAPEUTICS INC NEW | 8 | Q3 2023 | 14.4% |
| VAXCYTE INC | 8 | Q3 2023 | 10.9% |
| VERA THERAPEUTICS INC | 8 | Q3 2023 | 6.9% |
| TRAVERE THERAPEUTICS INC | 8 | Q3 2023 | 7.6% |
| VIRIDIAN THERAPEUTICS INC | 8 | Q3 2023 | 4.6% |
| BURNING ROCK BIOTECH LTD | 8 | Q3 2023 | 3.4% |
| AMARIN CORP PLC | 8 | Q3 2023 | 4.0% |
| LIQUIDIA CORPORATION | 8 | Q3 2023 | 3.6% |
| WAVE LIFE SCIENCES LTD | 8 | Q3 2023 | 3.7% |
View Kynam Capital Management, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-03-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-01-10 |
View Kynam Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.